Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Feb 7;114(2):320-321.
doi: 10.1093/jnci/djab154.

RE: Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study

Chen Nahshon  1 , Ofer Lavie  1
Affiliations
Editorial

RE: Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study

Chen Nahshon et al. J Natl Cancer Inst. .
No abstract available

PubMed Disclaimer

Comment in

  • Response to Nahshon and Lavie.
    de Kroon CD, de Jonge MM, Bosse T, van Asperen CJ. de Kroon CD, et al. J Natl Cancer Inst. 2022 Feb 7;114(2):322-323. doi: 10.1093/jnci/djab155. J Natl Cancer Inst. 2022. PMID: 34424271 Free PMC article. No abstract available.

Comment on

  • Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
    de Jonge MM, de Kroon CD, Jenner DJ, Oosting J, de Hullu JA, Mourits MJE, Gómez Garcia EB, Ausems MGEM, Margriet Collée J, van Engelen K, van de Beek I; Hebon Group; Smit VTHBM, Rookus MA, de Bock GH, van Leeuwen FE, Bosse T, Dekkers OM, van Asperen CJ. de Jonge MM, et al. J Natl Cancer Inst. 2021 Sep 4;113(9):1203-1211. doi: 10.1093/jnci/djab036. J Natl Cancer Inst. 2021. PMID: 33710348 Free PMC article.
  • Response to Nahshon and Lavie.
    de Kroon CD, de Jonge MM, Bosse T, van Asperen CJ. de Kroon CD, et al. J Natl Cancer Inst. 2022 Feb 7;114(2):322-323. doi: 10.1093/jnci/djab155. J Natl Cancer Inst. 2022. PMID: 34424271 Free PMC article. No abstract available.

References

    1. de Jonge MM, de Kroon CD, Jenner DJ, et al.Endometrial cancer risk in women with germline BRCA1 or BRCA2 mutations: multicenter cohort study. JNCI J Natl Cancer Inst. 2021;113(9):1203–1211. - PMC - PubMed
    1. Sherman ME, Foulkes WD.. BRCA1 /2 and endometrial cancer risk: implications for management. JNCI J Natl Cancer Inst. 2021;113(9)-1217–1218. - PMC - PubMed
    1. Nahshon C, Segev Y, Gemer O, et al.Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients–a systematic review and meta-analysis. Gynecol Oncol. 2021;160(3):755–762. - PubMed
    1. Gehrig PA, Bae-Jump VL, Boggess JF, et al.Association between uterine serous carcinoma and breast cancer. Gynecol Oncol. 2004;94(1):208–211. - PubMed
    1. Guo J, Zhang Y, Qian H, et al.The clinical characteristics and prognosis of endometrial carcinomas that occur after breast cancer: does hormone receptor status of breast cancer matter? Arch Gynecol Obstet. 2019;300(5):1399–1404. - PubMed